Lv1
38 积分 2025-08-31 加入
Association between anti-rituximab antibodies and treatment efficacy of rituximab in membranous nephropathy
4个月前
已完结
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy
4个月前
已完结
Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation
4个月前
已完结
Urinary rituximab loss and rate of treatment failure in membranous nephropathy
4个月前
已完结
Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies
5个月前
已完结
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
5个月前
已完结
Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study
10个月前
已完结
Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study
10个月前
已完结
Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy
10个月前
已完结
Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines
10个月前
已完结
皖公网安备34019202002308
